Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $8.00 Consensus Target Price from Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned an average rating of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.00.

Several equities analysts have recently weighed in on SRTS shares. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd.

Insider Buying and Selling at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta purchased 7,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average cost of $3.93 per share, with a total value of $27,510.00. Following the transaction, the director owned 140,113 shares in the company, valued at approximately $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Joseph C. Sardano purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was bought at an average price of $4.03 per share, with a total value of $100,750.00. Following the completion of the acquisition, the chief executive officer owned 1,200,293 shares in the company, valued at $4,837,180.79. This represents a 2.13% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 33,000 shares of company stock worth $132,060 in the last 90 days. Company insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the stock. Opes Wealth Management LLC acquired a new position in Sensus Healthcare during the 3rd quarter worth approximately $50,000. Vise Technologies Inc. purchased a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $52,000. Mindset Wealth Management LLC raised its stake in shares of Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares during the period. Evernest Financial Advisors LLC acquired a new position in shares of Sensus Healthcare during the second quarter worth $255,000. Finally, Sachetta LLC boosted its stake in shares of Sensus Healthcare by 8.0% in the third quarter. Sachetta LLC now owns 139,008 shares of the company’s stock valued at $436,000 after purchasing an additional 10,333 shares during the period. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Stock Down 3.1%

SRTS stock opened at $4.76 on Thursday. The company has a market cap of $78.18 million, a price-to-earnings ratio of -25.05 and a beta of 1.21. The business has a fifty day simple moving average of $4.45 and a 200-day simple moving average of $3.93. Sensus Healthcare has a 52 week low of $3.03 and a 52 week high of $5.92.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.